Introduction: NUT carcinoma is a rare, aggressive and poorly differentiated neoplasm characterized by chromosomal rearrangement of the NUTM1 gene. It mainly affects midline structures, such as the head, neck and mediastinum, and is associated with an extremely poor prognosis. Diagnosis is challenging and treatment often has limited success. Objectives: To report a case of NUT carcinoma in a pediatric patient with involvement of the nasal cavity and orbit, highlighting the clinical evolution, therapeutic difficulties and transition to palliative care. Case Description: A 9-year-old male patient was diagnosed on November 19, 2024, with NUT carcinoma originating in the nasal cavity and right orbit. He presented progressive growth of the tumor mass in the middle third of the face on the right, exophthalmos on the right, and marked facial asymmetry. His secondary diagnosis was Autism Spectrum Disorder, which justified self-harm behaviors in the right eye. A computed tomography scan of the face showed a solid, expansive, and infiltrative lesion involving ethmoid cells, right orbit, nasal cavity, and right maxillary sinus, with bone erosion and cervical lymph node enlargement. The diagnosis was confirmed by histopathology and immunohistochemistry. Bone marrow biopsy revealed mild to moderate lymphoplasmacytosis, without neoplastic infiltration. Systemic staging was negative for distant metastases. The patient underwent emergency cytoreduction with vincristine, followed by the VACTC and ICE (without etoposide) chemotherapy protocols. There was significant progression of the disease, with an increase in facial mass, severe exophthalmos, self-inflicted ulceration, cervical lymphadenopathy, daily fever and severe pain. Laboratory tests showed progressive anemia, leukopenia, thrombocytopenia, elevated C-reactive protein (up to 211 mg/L) and lactic dehydrogenase (up to 1,701 U/L). Family meetings were held and palliative care was chosen. Symptomatic control was achieved with continuous infusion of morphine and midazolam, associated with rescue doses. The patient died in the ward, under comfort measures. Conclusion: The case illustrates the aggressiveness of NUT carcinoma in pediatric patients and the difficulties in diagnosing and managing this neoplasm, due to its nonspecific manifestations and resistance to conventional therapies. Despite intensive treatment, progression was inevitable, highlighting the need for early integration of palliative care to improve quality of life in the terminal phase.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
